Navigation Links
Potential Breakthrough Cancer Treatment Now Available From Vascular Designs
Date:9/2/2009

SAN JOSE, Calif., Sept. 2 /PRNewswire/ -- Vascular Designs, a medical device company, today announced that its IsoFlow(TM) infusion catheter has secured 510(k) marketing clearance by the U.S. Food and Drug Administration (FDA) for the direct delivery of medications into highly targeted areas. An important application of IsoFlow may be in the treatment of cancer.

(Photo:http://www.newscom.com/cgi-bin/prnh/20090902/SF69552)

The IsoFlow Infusion catheter enables sideways perfusion, which allows physicians to precisely target and isolate areas within the body where the infused drugs are delivered. With IsoFlow's unique design, medications can be delivered into areas that could not previously be treated directly, for instance, a cancerous tumor. According to numerous studies, this approach lets physicians increase drug concentrations at targeted sites while reducing systemic exposure, thereby improving efficacy and patient outcomes when treating illnesses such as cancer with chemotherapy.*

"In select clinical situations, the benefits of delivering a local endovascular drug dose without systemic exposure can reduce complications, improve results, and benefit patients," said Dr. Michael Dake, former chief of interventional radiology and current professor of cardiothoracic surgery at Stanford University School of Medicine. "The IsoFlow catheter facilitates the use of regional infusion therapies, especially in cases of challenging arterial anatomy where it helps achieve these promises of targeted delivery. IsoFlow is a valuable addition to our treatment arsenal."


'/>"/>

SOURCE Vascular Designs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Sundia Receives the Highest Growth Potential Award from Zhangjiang
2. Heat forms potentially harmful substance in high-fructose corn syrup
3. A potential therapeutic agent for hepatic fibrosis
4. Herb Shows Potential for Rheumatoid Arthritis
5. Hissey Kientz, LLP Warns Duragesic Patch Users about Potential Health Risks of Fentanyl Overdose
6. ARKRAY Statement Regarding U.S. Food and Drug Administrations Public Health Notification: Potentially Fatal Errors With GDH-PQQ Glucose Monitoring Technology
7. Researchers identify potential new avenue to attack cancer
8. OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma
9. Frost & Sullivan: Outsourcing/Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market
10. Large Majority of Drivers 55 and Older Unaware of Potentially Dangerous Combination of Medications and Driving, Says New AAA Foundation Study
11. New class of compounds discovered for potential Alzheimers disease drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 29, 2015 Johnson & ... a confidential Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) settlement ... due to his use of the antipsychotic medication. ... selected for the third bellwether trial to involve ... litigation underway in Pennsylvania’s Philadelphia Court of Common ...
(Date:5/29/2015)... California (PRWEB) May 29, 2015 A group ... and have joined the national effort to teach this “new ... in the U.S. have been “sickened” by the recent implementation ... love it or hate it, Common Core is now a ... of Columbia. Parents are now seeking ways to improve ...
(Date:5/29/2015)... May 29, 2015 Intermountain ... partnered with Stratus Video Interpreting ... facilitate better communication and timely care for ... hearing loss. Stratus’ video remote interpreting (VRI) ... enabling staff to quickly access qualified medical ...
(Date:5/29/2015)... The print component of “Skin Health” ... approximately 250,000 and an estimated readership of 750,000. The ... media strategy, and across a network of top news ... of the campaign, click here. , Lucy ... the actress, model and producer details her skin care ...
(Date:5/29/2015)... NY (PRWEB) May 29, 2015 Mediaplanet ... the “beauty of protection”. Skin Health is a ... Today within the markets of New York, Los Angeles, ... estimated 750,000 readers. Its digital counterpart will reach a ... hubs. To read more the Skin Health campaign and ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3Health News:Doctors Discover a Cure for the Common Core 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2
... new type of stem cell discovered in the prostate ... cancer, according to a new study by researchers at ... Medical Center and NewYork-Presbyterian Hospital. Led by Michael ... at Columbia University Medical Center, the researchers found the ...
... 9 /PRNewswire-FirstCall/ - The following two issuers (HTDS) ... that further to their previous news releases announcing their ... OTCBB both issuers have retained an SEC qualified auditor ... firm, Mina Mar Group is providing this notice to ...
... , More than 1.3 million Americans go on ... , WASHINGTON, Sept. 9 Leading opponents of government-run health ... for Policy Analysis (NCPA) and Salem Radio Network delivered the more than ... to Congress at a rally held on Capitol Hill. , , ...
... , , , , ... Education Verification (OEV) Program meets the new CMS requirements for verification calls. ... multiple carriers and a variety of plan types. , , ... enrolled members to confirm their intent to enroll in the plan, ensure ...
... ... Cell and Drug DevelopmentTM" including products for use in cancer stem cell research. ... newly developed drugs that block a biological pathway (hedge hog) that drives the proliferation ... ...
... , , ROCHESTER, ... Innovation will host Transform, a collaborative symposium on innovations ... http://centerforinnovation.mayo.edu/transform . Transform will feature nationally recognized ... in health care delivery models, including Web-based tools. The ...
Cached Medicine News:Health News:New type of adult stem cells found in the prostate may be involved in prostate cancer development 2Health News:Hard to Treat Diseases, Inc. (HTDS) and Landstar Inc (LDSR) Retain Auditors 2Health News:Hard to Treat Diseases, Inc. (HTDS) and Landstar Inc (LDSR) Retain Auditors 3Health News:National Center for Policy Analysis and Salem Radio Network Deliver Million-Plus Signature Petition Opposing Government Run Health Care 2Health News:National Center for Policy Analysis and Salem Radio Network Deliver Million-Plus Signature Petition Opposing Government Run Health Care 3Health News:DSS Research Announces Outbound Education and Verification Program Meets New CMS Requirements 2Health News:Vitro's Cancer Stem Cell Therapy Complements New Hedge Hog Drugs 2Health News:Vitro's Cancer Stem Cell Therapy Complements New Hedge Hog Drugs 3Health News:Vitro's Cancer Stem Cell Therapy Complements New Hedge Hog Drugs 4Health News:Mayo Clinic Center for Innovation Collaborative Symposium on Innovations in Health Care Experience 2Health News:Mayo Clinic Center for Innovation Collaborative Symposium on Innovations in Health Care Experience 3Health News:Mayo Clinic Center for Innovation Collaborative Symposium on Innovations in Health Care Experience 4
(Date:5/29/2015)... British Columbia and MENLO ... -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ... on developing and commercializing proven cancer therapies in ... at the American Association of Cancer Research ... on the potential for its lead product candidate ...
(Date:5/29/2015)... INDIANAPOLIS , May 29, 2015  Eli Lilly ... AZN ) today announced that they have entered ... and preliminary efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint ... Lilly,s VEGF Receptor 2 antiangiogenic cancer medicine. The planned ... patients with advanced solid tumors. The Phase ...
(Date:5/29/2015)... , May 29, 2015  World-renowned prostate surgeon and New ... on the benefit of MR/Ultrasound Fusion-Guided Biopsy for ... Prostate Cancer Center at Lenox Hill Hospital is ... System in New York City . We,ve ... risk prostate cancers. The use of an MRI makes for ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2
... Mass., April 9, 2008 /PRNewswire-FirstCall/ - Echo,Therapeutics ... results,from its human feasibility study of the ... permeation medium for its,Symphony(TM) tCGM System, a ... development for diabetes home use and hospital ...
... April 8, 2008 The Association,for Professionals in ... L. Stricof, MT, MPH, of Albany, NY, has ... DeMille Achievement Award.,APIC presents the annual award to ... the ideals of Carole DeMille, a pioneer,in infection ...
Cached Medicine Technology:Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System 2Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System 3Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System 4Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System 5New York Infection Prevention Expert Named Recipient of Carole DeMille Award 2
Inquire...
Inquire...
... EDTA K2 or EDTA K3 tubes. ... therefore blocks the coagulation cascade. Erythrocytes, ... anticoagulated blood sample are stable for ... are for the examination of whole ...
... the most powerful, productive ... and rich in features, ... a comprehensive authoring environment ... custom interactive multimedia content ...
Medicine Products: